{"id":44820,"date":"2022-06-07T23:01:21","date_gmt":"2022-06-07T21:01:21","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\/"},"modified":"2022-06-07T23:01:21","modified_gmt":"2022-06-07T21:01:21","slug":"aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\/","title":{"rendered":"Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease"},"content":{"rendered":"
\n

LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc.<\/a> (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Wednesday, June 8, 2022, at 8:00 a.m. (ET) to provide top-line results from the Phase 3 TRANQUILITY-2 Trial of reproxalap in dry eye disease.\n<\/p>\n

<\/a><\/p>\n

\nThe dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 for international callers. The access code is 879247. A live audio webcast of the conference call also will be accessible from the \u201cInvestors & Media\u201d section of Aldeyra’s website at ir.aldeyra.com<\/a>.\n<\/p>\n

\nAfter the live webcast, the event will remain archived on Aldeyra\u2019s website for 90 days.\n<\/p>\n

\nAbout Aldeyra<\/i><\/b>\n<\/p>\n

\nAldeyra develops innovative therapies designed to treat immune-mediated diseases. Our approach is to discover pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 clinical testing for the treatment of systemic immune-mediated diseases. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit https:\/\/www.aldeyra.com<\/a> and follow us on LinkedIn<\/a>, Facebook<\/a>, and Twitter<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors & Media:<\/b>
Scott Solomon
\n
Sharon Merrill Associates, Inc.
\n
Tel: (857) 383-2409
\n
ALDX@investorrelations.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Wednesday, June 8, 2022, at 8:00 a.m. (ET) to provide top-line results from the Phase 3 TRANQUILITY-2 Trial of reproxalap in dry eye disease. The dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44820","6":"format-standard","7":"category-industry"},"yoast_head":"\nAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Wednesday, June 8, 2022, at 8:00 a.m. (ET) to provide top-line results from the Phase 3 TRANQUILITY-2 Trial of reproxalap in dry eye disease. The dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-07T21:01:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220607006078\/en\/1479141\/21\/ALDX_logo_JPEG.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease\",\"datePublished\":\"2022-06-07T21:01:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\\\/\"},\"wordCount\":273,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220607006078\\\/en\\\/1479141\\\/21\\\/ALDX_logo_JPEG.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\\\/\",\"name\":\"Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220607006078\\\/en\\\/1479141\\\/21\\\/ALDX_logo_JPEG.jpg\",\"datePublished\":\"2022-06-07T21:01:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220607006078\\\/en\\\/1479141\\\/21\\\/ALDX_logo_JPEG.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220607006078\\\/en\\\/1479141\\\/21\\\/ALDX_logo_JPEG.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\/","og_locale":"en_US","og_type":"article","og_title":"Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease - Pharma Trend","og_description":"LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Wednesday, June 8, 2022, at 8:00 a.m. (ET) to provide top-line results from the Phase 3 TRANQUILITY-2 Trial of reproxalap in dry eye disease. The dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-07T21:01:21+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220607006078\/en\/1479141\/21\/ALDX_logo_JPEG.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease","datePublished":"2022-06-07T21:01:21+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\/"},"wordCount":273,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220607006078\/en\/1479141\/21\/ALDX_logo_JPEG.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\/","url":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\/","name":"Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220607006078\/en\/1479141\/21\/ALDX_logo_JPEG.jpg","datePublished":"2022-06-07T21:01:21+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220607006078\/en\/1479141\/21\/ALDX_logo_JPEG.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220607006078\/en\/1479141\/21\/ALDX_logo_JPEG.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44820","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44820"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44820\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44820"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44820"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44820"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}